Association between allopurinol and mortality in heart failure patients: A long-term follow-up study

International Journal of Clinical Practice

Volumn 63, Issue 9, 2009, Pages 1327-1333

  Wei, L ^a   Fahey, T ^b   Struthers, A D ^a   MacDonald, T M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; SPIRONOLACTONE; TORASEMIDE; CARDIOVASCULAR AGENT; LOOP DIURETIC AGENT;

AGED; ANGINA PECTORIS; ARTICLE; CARDIAC PATIENT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG USE; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; RECURRENT DISEASE; STROKE; SURVIVAL TIME; TRANSIENT ISCHEMIC ATTACK; UNITED KINGDOM; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; DOSE RESPONSE; KAPLAN MEIER METHOD; MULTICENTER STUDY; STATISTICS AND NUMERICAL DATA;

AGED; ALLOPURINOL; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MYOCARDIAL INFARCTION; RECURRENCE; SCOTLAND; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 68949215869     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02118.x     Document Type: Article

References (26)

1. Anker SD, Doehner W, Rauchhaus M et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003 107 : 1991 1997. Epub 21 April 2003.
2. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality. The NHANES 1 epidemiologic follow-up study, 1971-1992. JAMA 2000 283 : 2404 2410.
3. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003 34 : 1951 1956. Epub 3 July 2003.
4. Niskanen LK, Laaksonen DE, Nyyssönen K et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004 164 : 1546 1551.
5. Strasak A, Ruttmann E, Brant L et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83 683 Austrian men. Clin Chem 2008 54 : 273 284. Epub 26 November 2007.
6. Engberding N, Spiekermann S, Schaefer A et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 2004 110 : 2175 2179. Epub 4 October 2004.
7. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006 114 : 2508 2516. Epub 27November 2006.
8. Doehner W, Schoene N, Rauchhaus M et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002 105 : 2619 2624.
9. Struthers AD, Donnan PT, Lindsay P, Mcnaughton D, Broomhall J, MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002 87 : 229 234.
10. Landmesser U, Drexler H. Allopurinol and endothelial function in heart failure: future or fantasy? Circulation 2002 106 : 173 175.
11. Wei L, Parkinson J, MacDonald TM 2005) The Tayside Medicines Monitoring Unit (MEMO). In : Strom BL, ed. Pharmacoepidemiology, 4th edn. Chichester : John Wiley and Sons, pp. 323 336.
12. Libby G, MacDonald TM, Evans JM. Record-linkage methodology for prescribing research. J Clin Pharm Ther 2001 26 : 241 246.
13. Struthers AD, Anderson G, Donnan PT, MacDonald T. Social deprivation increases cardiac hospitalisations in chronic heart failure independent of disease severity and diuretic non-adherence. Heart 2000 83 : 12 6.
14. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002 359 : 118 123.
15. ISD Scotland. Data Quality Assurance. http://www.isdscotland.org/isd/ 4943.html (accessed April 2009).
16. Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol 2008 167 : 492 499. Epub 3 December 2007. Review.
17. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006 58 : 87 114.
18. Short RA, Johnson RJ, Tuttle KR. Uric acid, microalbuminuria and cardiovascular events in high-risk patients. Am J Nephrol 2005 25 : 36 44. Epub 21 February 2005.
19. Aengevaeren WR. Beyond lipids - the role of the endothelium in coronary artery disease. Atherosclerosis 1999 147 (Suppl 1) S11 6. Review.
20. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999 131 : 7 13.
21. Heitzer T, Baldus S, von Kodolitsch Y, Rudolph V, Meinertz T. Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure. Arterioscler Thromb Vasc Biol 2005 25 : 1174 1179. Epub 14 April 2005.
22. MacDonald TM, Morant SV, Robinson GC et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997 315 : 1333 1337.
23. Beardon PHG, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary non-compliance with prescribed medication in primary care. BMJ 1993 307 : 846 848.
24. Muir SW, Harrow C, Dawson J et al. Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial. Stroke 2008 39 : 3303 3307. Epub 9 October 2008.
25. Strom BL, ed. Automated Data Systems Available for Pharmacoepidemiology Studies. Pharmacoepidemiology, 4th edn. Chichester : John Wiley and Sons, 2005 : 217 337.
26. MacGregor A, Wardle H. Scottish Health Survey, 2003. Volume 2: Adult. 39-74. http://www.scotland.gov.uk/Resource/Doc/76169/0019729.pdf (accessed June 2009).